Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).